Navigation Links
Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
Date:10/31/2007

ALBUQUERQUE, N.M., Oct. 31 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today it hired Manzano Strategies LLC, a government consulting firm focused on building government partnerships with companies interested in defense appropriations and development of advanced technologies.

Manzano Strategies' (http://www.manzanostrategies.com) partners David Montoya and Bruce Donisthorpe will spearhead efforts with the New Mexico legislature and federal government in promoting programs using Biomoda's early lung cancer detection technology based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope.

Before launching Manzano Strategies, Montoya served as Chief of Staff of Los Alamos National Laboratory's Nuclear Weapons Program. He served as a senior policy advisor to Senator Jeff Bingaman, responsible for defense, veterans' affairs, economic development and other programs. Donisthorpe was Legislative Director for Representative Joe Skeen and an Associate Staff Member of the US House Appropriations Committee prior to entering private business as a government affairs advisor for New Mexico Institute of Mining and Technology (New Mexico Tech), among other high-technology and defense- related clients.

"David and Bruce represent two of the best advisors in the country related to our work with the government in securing support for programs that will help our veterans and the military in the field of health care," said John Cousins, President of Biomoda. "We look forward to using every bit of their expertise in promoting Biomoda on a national scale."

Biomoda's, the patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins (505) 821-0875


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. Merge Healthcare hires new VP of finance
3. PDS hires new VP, buys former health club building
4. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
5. Going for the "Big Score" or hedging your bets: Two economic development strategies
6. Innovative Health Strategies near Milwaukee set to profit from Medicare expansion
7. Entrepreneurs Conference to focus on strategies, tools and culture
8. Sales Strategies for the High-Tech Entrepreneur
9. Spend Money to Make Money and Dump Obsolete Tech Strategies
10. Institute Helps Industries Enhance Business Strategies
11. GameBased Learning Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):